CD163 and central nervous system cancer: Increased numbers of CD68+ and higher ratio of CD163/AIF+ cells, as TAMs markers, and more FOXP3+ cells were associated with shorter progression-free survival, while high CD3+ and CD8+ T cells accompanied by low CD68+ and high IDO+ cell counts were associated with better glioma prognosis [76].